Uncategorized
Director/Vice President of Translational Research: Leading the Bridge from Discovery to Clinical Development
Translational Research, Biomarker Discovery, Preclinical Development, Early Clinical Development, Drug Molecule Development, Translational Science Leadership, Biomarker Development, Target Engagement Strategies, Assay Development (PK/ PD/ Immunogenicity), Clinical Trial Design, Endpoint and Biomarker Strategy, Team Building and Leadership, Cross-Functional Collaboration, Regulatory Approvals
Roche’s Ocrevus Demonstrates Near-Complete Reduction of Relapse and Lesions in Multiple Sclerosis
Ocrevus, Roche, Multiple Sclerosis (MS), Relapse reduction, Lesion reduction, Clinical and MRI measures
Canaan Secures Additional $100M for Biopharma Fund and Welcomes Pfizer Veteran to Team
Canaan, Biopharma Fund, $100M Investment, Pfizer Veteran
Sage Therapeutics’ Dalzanemdor Outcomes Amid Parkinson’s Miss
Sage Therapeutics Dalzanemdor Parkinson
Sanofi Downsizes IGM Antibody Deal, Reduces Oncology Focus
Sanofi, IGM Biosciences, antibody deal, oncology, downsizing, partnership
Eli Lilly’s Zepbound Shows Promising Results in Reducing Sleep Apnea Severity in Pivotal Trials
Eli Lilly, Zepbound, Sleep Apnea, Obstructive Sleep Apnea (OSA), Pivotal Trials, Obesity, GLP-1 Receptor Agonist, Tirzepatide, CPAP, Weight Loss
Detailed PHOENIX Study Reveals Relyvrio’s Failure in ALS Treatment
Relyvrio, PHOENIX study, Amyotrophic Lateral Sclerosis (ALS), Trial failure, Amylyx Pharmaceuticals
AbbVie Secures Deal with Medincell for Long-Acting Injectable Platform, Valued up to $1.9 Billion
AbbVie, Medincell, Long-acting injectable platform, Biotechnology, Deal, $1.9 billion
CMS to Increase Reimbursement for New Sickle Cell Gene Therapies through Outcomes-Based Agreements
CMS (Centers for Medicare & Medicaid Services), Sickle Cell Gene Therapies, Increased Reimbursement, Outcomes-Based Agreements (OBAs), Cell and Gene Therapy (CGT) Access Model, Medicaid Access, Casgevy, Lyfgenia, Fertility Preservation Services, Equitable Access, Administrative Burden Reduction
Intra-Cellular’s Caplyta Triumphs in Major Depressive Disorder Phase 3 Trial, Edging Closer to FDA Filing
Intra-Cellular Therapies, Caplyta, Lumateperone, Major Depressive Disorder (MDD), Phase 3 Trial, Positive Results, Statistically Significant, Clinically Meaningful, Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impression Scale for Severity of Illness (CGI-S), FDA Filing